Since there are no published trials comparing anti‐PD‐1 and anti‐PD‐L1 in untreated metastatic NSCLC, the present data highlights that different ICIs might have distinct efficacy and toxicity in this population. This evidence concerns the gene CD274 and non-small cell lung carcinoma.